Skip to main content

Your Source for Leading Voices and Key Developments in EGFRm NSCLC

Latest News

Top 5 Highlights from ASCO 2026
Top 5 Highlights from ASCO 2026News & Conference Highlights

Top 5 Highlights from ASCO 2026

June 11, 2026
Top 5 Highlights from AACR 2026
Top 5 Highlights from AACR 2026News & Conference Highlights

Top 5 Highlights from AACR 2026

June 11, 2026
Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC
Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLCNews & Conference Highlights

Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC

June 8, 2026

Latest News

Top 5 Highlights from ASCO 2026
Top 5 Highlights from ASCO 2026News & Conference Highlights

Top 5 Highlights from ASCO 2026

June 11, 2026
Top 5 Highlights from AACR 2026
Top 5 Highlights from AACR 2026News & Conference Highlights

Top 5 Highlights from AACR 2026

June 11, 2026
Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC
Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLCNews & Conference Highlights

Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC

June 8, 2026

Downloadable Resources

Featured Downloadable Resources

View All
EGFR-Driven Solid Tumors Preclinical Data Thumbnail
Infographic

EGFR-Driven Solid Tumors Preclinical Data
EGFR-Mutated NSCLC: Acquired Resistance Thumbnail
Infographic

EGFR-Mutated NSCLC: Acquired Resistance
Top 5 Highlights From ELCC 2026 Thumbnail
Infographic

Top 5 Highlights From ELCC 2026

Expert Insights

View All

High-level synthesis, interpretation, and clinical framing from established thought leaders.

Introduction and Frontline Regimen Selection in EGFR-Mutant NSCLC
Introduction and Frontline Regimen Selection in EGFR-Mutant NSCLCExpert Insights

Introduction and Frontline Regimen Selection in EGFR-Mutant NSCLC

May 11, 2026
Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS Surveillance
Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS SurveillanceExpert Insights

Managing Progression in EGFR-Mutant NSCLC: Re-Biopsy, Small Cell Transformation, and CNS Surveillance

May 11, 2026
Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging EvidenceExpert Insights

Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence

May 11, 2026
MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management
MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity ManagementExpert Insights

MET-Directed Resistance in EGFR-Mutant NSCLC: Testing, Treatment Matching, and Toxicity Management

May 11, 2026

News & Conference Highlights

View All

Rapid, curated interpretation of emerging data.

Top 5 Highlights from ASCO 2026
Top 5 Highlights from ASCO 2026News & Conference Highlights

Top 5 Highlights from ASCO 2026

June 11, 2026
Top 5 Highlights from AACR 2026
Top 5 Highlights from AACR 2026News & Conference Highlights

Top 5 Highlights from AACR 2026

June 11, 2026
Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC
Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLCNews & Conference Highlights

Adjuvant Erlotinib Does Not Improve OS Over Observation in Resected EGFR-Mutant NSCLC

June 8, 2026
FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC
FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLCNews & Conference Highlights

FLAME Study Shows Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent EGFR-Mutant NSCLC

June 8, 2026

Emerging Voices in EGFR Care

View All

Highlight next-generation oncologists with fresh, pragmatic viewpoints.

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MScEmerging Voices in EGFR Care

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

November 14, 2025

How I Treat

View All

Practical, case-based, scenario-based, decision-oriented content.

EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy
EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination TherapyHow I Treat

EGFR-Mutated NSCLC: De-escalation of Chemotherapy in Combination Therapy

April 28, 2026
EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment
EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line TreatmentHow I Treat

EGFR-Mutated NSCLC: Importance of CNS Efficacy in First-Line Treatment

April 28, 2026
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case
EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved CaseHow I Treat

EGFR-Mutated NSCLC: First-Line Treatment Selection in a CNS-Involved Case

April 21, 2026
EGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment Evaluation
EGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment EvaluationHow I Treat

EGFR-Mutated NSCLC: Role of Value-Based Frameworks in Treatment Evaluation

April 21, 2026

Clinical Updates Calendar

Mo
Tu
We
Th
Fr
Sa
Su
Anticipated Decisions
Approvals
Conferences
Data Readouts
Designations
Events This Month

Funding for the EGFR Channel is provided by AstraZeneca. All content is developed independently by MJH Life Sciences; AstraZeneca has no influence on the content of the site.

© 2026 MJH Life Sciences. All rights reserved.

Home
Clinical Updates Calendar
View All Resources